Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.

doi:10.1016/j.ejca.2024.114204

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2024

Hochmair Maximilian J, Vermaelen Karim, Mountzios Giannis, Carcereny Enric, Dooms Christophe, Lee Se-Hoon, Morocz Eva, Kato Terufumi, Ciuleanu Tudor-Eliade, Dy Grace K, Parente Barbara, O'Byrne Kenneth J, Chu Quincy S, Castro Junior Gilberto De, Girard Nicolas, Snyder Wendy, Tran Qui, Kormany William, Houk Brett, Mehta Bhakti, Curioni-Fontecedro Alessandra

Abstract excerpt

BACKGROUND: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg. METHODS: In this phase 2, randomized, open-label study, adults with KRAS G12C-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Lung Neoplasms

Share to Piperazines

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 39029295
DOI: 10.1016/j.ejca.2024.114204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.PMID 39029295Read ↗

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.Semantic proximity Read ↗

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read ↗

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.Semantic proximity Read ↗

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.Semantic proximity Read ↗

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].Semantic proximity Read ↗

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.Semantic proximity Read ↗

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.